Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
When considering these alternatives, it's essential to consult healthcare professionals and monitor health metrics to avoid potential risks associated with peptide use
However, published data allows a directional comparison of the most common GI events: Adverse Event Retatrutide (12 mg) Semaglutide 2.4 mg (STEP trials) Tirzepatide 15 mg (SURMOUNT trials) Nausea ~46% ~44% ~31% Diarrhea ~33% ~30% ~23% Vomiting ~22% ~24% ~12% Constipation ~17% ~24% ~12% Important caveat: These numbers come from different trial populations and cannot be directly compared
To determine ROS production, cells were incubated with DCFH-DA (10 M) for 30 min, washed twice with cold PBS
The medication is marketed by the brand names Zepbound and Mounjaro
